Canadian hereditary angioedema guideline
详细信息    查看全文
  • 作者：Stephen Betschel (1)
    Jacquie Badiou (2)
    Karen Binkley (1)
    Jacques H茅bert (3)
    Amin Kanani (4)
    Paul Keith (5)
    Gina Lacuesta (6)
    Bill Yang (7)
    Emel Ayg枚ren-P眉rs眉n (8)
    Jonathan Bernstein (9)
    Konrad Bork (10)
    Teresa Caballero (11)
    Marco Cicardi (12)
    Timothy Craig (13)
    Henriette Farkas (14)
    Hilary Longhurst (15)
    Bruce Zuraw (16)
    Henrik Boysen (17)
    Rozita Borici-Mazi (18)
    Tom Bowen (19)
    Karen Dallas (20)
    John Dean (21)
    Kelly Lang-Robertson (1)
    Beno卯t Laram茅e (22)
    Eric Leith (23)
    Sean Mace (1)
    Christine McCusker (24)
    Bill Moote (25)
    Man-Chiu Poon (26)
    Bruce Ritchie (27)
    Donald Stark (4)
    Gordon Sussman (1)
    Susan Waserman (5)

    1. University of Toronto     ; Toronto ; Ontario ; Canada
    2. HAE Canada     ; Notre Dame des Lourdes ; Manitoba ; Canada
    3. Department of Medicine     ; Laval University ; Quebec City ; Quebec ; Canada
    4. Department of Medicine     ; University of British Columbia ; Vancouver ; British Columbia ; Canada
    5. Department of Medicine     ; McMaster University ; Hamilton ; Ontario ; Canada
    6. Department of Medicine     ; Dalhousie University ; Halifax ; Nova Scotia ; Canada
    7. University of Ottawa Medical School     ; Ottawa ; Ontario ; Canada
    8. Goethe-Universit盲t Frankfurt am Main     ; Frankfurt am Main ; Germany
    9. Department of Internal Medicine     ; University of Cincinnati ; Cincinnati ; Ohio ; USA
    10. Department of Dermatology     ; University Hospital of the Johannes Gutenberg-University of Mainz ; Mainz ; Germany
    11. Hospital La Paz Health Research Institute     ; Madrid ; Spain
    12. Department of Internal Medicine     ; UniversitadegliStudi di Milano ; Ospedale L. Sacco ; Milan ; Italy
    13. Departments of Medicine and Pediatrics     ; Penn State University ; Hershey ; Pennsylvania ; USA
    14. 3rd Department of Internal Medicine     ; Faculty of Medicine ; Semmelweis University ; Budapest ; Hungary
    15. Department of Immunology     ; Barts and the London NHS Trust ; London ; England ; UK
    16. University of California     ; San Diego ; San Diego ; California ; USA
    17. HAE International     ; Skanderborg ; Denmark
    18. Department of Medicine     ; Queen鈥檚 University ; Kingston ; Ontario ; Canada
    19. Departments of Medicine and Paediatrics     ; University of Calgary ; Calgary ; Alberta ; Canada
    20. Saskatoon Health Region     ; Saskatoon ; Saskatchewan ; Canada
    21. BC Children鈥檚 Hospital     ; Vancouver ; British Columbia ; Canada
    22. Centre hospitalier de l鈥檜niversit茅 de Montr茅al     ; Montr茅al ; Quebec ; Canada
    23. Department of Medicine     ; University of Toronto ; Oakville ; Ontario ; Canada
    24. Department of Immunology     ; McGill University Health Centre ; Montreal ; Quebec ; Canada
    25. Department of Medicine     ; Western University ; London ; Ontario ; Canada
    26. Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program     ; Calgary ; Alberta ; Canada
    27. Departments of Medicine and Medical Oncology     ; University of Alberta ; Edmonton ; Alberta ; Canada
  • 关键词：Hereditary angioedema ; Guideline ; Recommendations ; Acute attacks ; Short ; term prophylaxis ; Long ; term prophylaxis ; Self ; administration ; Individualized therapy ; Quality of life ; Comprehensive care ; GRADE
  • 刊名：Allergy, Asthma & Clinical Immunology
  • 出版年：2014
  • 出版时间：December 2014
  • 年：2014
  • 卷：10
  • 期：1
  • 全文大小：472 KB
  • 参考文献：1. Cicardi, M, Agastoni, A (1996) Hereditary Angioedema. N Engl J Med 334: pp. 1666-1667 CrossRef
    2. Zuraw, BL (2008) Clinical practice. Hereditary angioedema. N Engl J Med 359: pp. 1027-1036 CrossRef
    3. Bork, K, Hardt, J, Witzke, G (2012) Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol 130: pp. 692-697 CrossRef
    4. Zilberberg, MD, Jacobsen, T, Tillotson, G (2010) The burden of hospitalizations and emergency department visits with hereditary angioedema and angioedema in the United States 2007. Allergy Asthma Proc 31: pp. 511-519 CrossRef
    5. Agostoni, A, Aygoren-Pursun, E, Binkley, KE, Blanch, A, Bork, K, Bouillet, L (2004) Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 114: pp. S51-S131 CrossRef
    6. Kaplan, AP, Joseph, K, Silverberg, M (2002) Pathways for Bradykinin Formation and Inflammatory Disease. J Allergy Clin Immunol 109: pp. 195-209 CrossRef
    7. Gompels, MM, Lock, RJ, Morgan, JE, Osborne, J, Brown, A, Virgo, PF (2002) A multicentre evaluation of the diagnostic efficiency of serological investigations for C1 inhibitor deficiency. J Clin Pathol 55: pp. 145-147 CrossRef
    8. Tarzi, MD, Hickey, A, Forster, T, Mohammadi, M, Longhurst, HJ (2007) An evaluation of tests used for the diagnosis and monitoring of C1 Inhibitor Deficiency: Normal serum C4 does not exclude hereditary angioedema. Clin Exp Immunol 149: pp. 513-516 CrossRef
    9. Bowen, T, Cicardi, M, Farkas, H, Bork, K, Longhurst, HJ, Zuraw, B, Aygoeren-P眉rs眉n, E, Craig, T, Binkley, K, Hebert, J, Ritchie, B, Bouillet, L, Betschel, S, Cogar, D, Dean, J, Devaraj, R, Hamed, A, Kamra, P, Keith, PK, Lacuesta, G, Leith, E, Lyons, H, Mace, S, Mako, B, Neurath, D, Poon, MC, Rivard, GE, Schellenberg, R, Rowan, D, Rowe, A (2010) 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 6: pp. 24 CrossRef
    10. Cicardi, M, Bork, K, Caballero, T, Craig, T, Li, HH, Longhurst, H, Reshef, A, Zuraw, B (2012) HAWK (Hereditary Angioedema International Working Group). Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 67: pp. 147-157 CrossRef
    11. Bork, K (2009) Hereditary angioedema with normal C1 inhibitor. Curr Allergy Asthma Rep 9: pp. 280-285 CrossRef
    12. Bork, K (2013) Hereditary angioedema with normal C1 inhibitor. Immunol Allergy Clin N Am 33: pp. 457-470 CrossRef
    13. Cicardi, M (2014) Classification, diagnosis, and approach to treatment for angioedema: Consensus report from the Hereditary Angioedema International Working Group. Allergy 69: pp. 602-616 CrossRef
    14. / http://www.uspreventativeservicestaskforce.org.
    15. Craig, T (2012) WAO Guideline for the Management of Hereditary Angioedema. World Allergy Organ J 5: pp. 182-199 CrossRef
    16. Balshem, H, Helfand, M, Schunemann, HJ, Oxman, AD, Kunz, R, Brozek, J (2011) GRADE guidelines 3: Rating the quality of evidence. J Clin Epidemiol 64: pp. 401-406 CrossRef
    17. Andrews, JC, Schunemann, HJ, Oxman, AD, Pottie, K, Meerpohl, JJ, Coello, PA (2013) GRADE guidelines: 15. Going from evidence to recommendation鈥攄eterminants of a recommendation鈥檚 direction and strength. J Clin Epidemiol 66: pp. 726-735 CrossRef
    18. Guyatt, GH, Oxman, AD, Kunz, R, Falck-Ytter, Y, Vist, GE, Liberati, A (2008) Rating quality of evidence and strength of recommendations: Going from evidence to recommendations. BMJ 336: pp. 1049-1051 CrossRef
    19. Higgins JPT, Green S (Eds): The Cochrane Collaboration In / Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] 2011. Available from http://www.cochrane-handbook.org
    20. Cicardi, M, Banerji, A, Bracho, F, Malbran, A, Rosenkranz, B, Riedl, M (2010) Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 363: pp. 532-541 CrossRef
    21. Cicardi, M, Levy, RJ, McNeil, DL, Li, HH, Sheffer, AL, Campion, M (2010) Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 363: pp. 523-531 CrossRef
    22. Craig, TJ, Levy, RJ, Wasserman, RL, Bewtra, AK, Hurewitz, D, Obtulowicz, K (2009) Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 124: pp. 801-808 CrossRef
    23. Kunschak, M, Engl, W, Maritsch, F, Rosen, FS, Eder, G, Zerlauth, G (1998) A randomized, controlled trial to study the efficacy and safety of C1-INH concentrate in treating hereditary angioedema. Transfusion 38: pp. 540-549 CrossRef
    24. Levy, RJ, Lumry, WR, McNeil, DL, Li, HH, Campion, M, Horn, PT (2010) EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 104: pp. 523-529 CrossRef
    25. Lumry, WR, Li, HH, Levy, RJ, Potter, PC, Farkas, H, Moldovan, D (2011) Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol 107: pp. 529-537 CrossRef
    26. Schneider, L, Lumry, W, Vegh, A, Williams, AH, Schmalbach, T (2007) Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J Allergy Clin Immunol 120: pp. 416-422 CrossRef
    27. Waytes, AT, Rosen, FS, Frank, MM (1996) Treatment of hereditary angioedema with a vapor-heated C1-INH concentrate. N Engl J Med 334: pp. 1630-1634 CrossRef
    28. Zuraw, B, Cicardi, M, Levy, RJ, Nuijens, JH, Relan, A, Visscher, S (2010) Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 126: pp. 821-827.e14 CrossRef
    29. Zuraw, BL, Busse, PJ, White, M, Jacobs, J, Lumry, W, Baker, J (2010) NanofilteredC1-INH concentrate for treatment of hereditary angioedema. N Engl J Med 363: pp. 513-522 CrossRef
    30. Hack, CE, Relan, A, van Amersfoort, ES, Cicardi, M (2012) Target levels of functional C1-inhibitor in hereditary angioedema. Allergy 67: pp. 123-130 CrossRef
    31. Donaldson, VH, Rosen, FS, Bing, DH, Kinin, (1983) Generation in Hereditary Angioneurotic Edema (H.A.N.E.) Plasma. J Adv Exp Med Biol 156: pp. 183-191
    32. Horn, PT, Li, HH, Pullman, WE (2010) Hypersensitivity reactions following ecallantide treatment for acute attacks of HAE. J Allergy Clin Immunol 126: pp. AB163
    33. Martinez-Saguer, I, Rusicke, E, Aygoren-Pursun, E, von Hentig, N, Klingebiel, T, Kreuz, W (2010) Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: a prospective study. Transfusion 50: pp. 354-360 CrossRef
    34. Longhurst, H (2008) Rhucin, a recombinant C1 inhibitor for the treatment of hereditary angioedema and cerebral ischemia. J Curr Opin Investig Drugs 9: pp. 310-323
    35. van Doorn, MB, Burggraaf, J, van Dam, T, Eerenberg, A, Levi, M, Hack, CE (2005) A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol 116: pp. 876-883 CrossRef
    36. Longhurst, HJ (2005) Emergency treatment of acute attacks in hereditary angioedema due to C1 inhibitor deficiency: what is the evidence?. Int J Clin Pract 59: pp. 594-599 CrossRef
    37. Prematta, M, Gibbs, JG, Pratt, EL, Stoughton, TR, Craig, TJ (2007) Fresh frozen plasma for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol 98: pp. 383-388 CrossRef
    38. Prematta, MJ, Bewtra, AK, Levy, RJ, Wasserman, RL, Jacobson, KW, Machnig, T, Craig, TJ (2012) Per-attack reporting of prodromal symptoms concurrent with C1 inhibitor treatment of hereditary angioedema attacks and. Adv Ther 10: pp. 913-922 CrossRef
    39. Kreuz, W, Martinez-Saguer, I, Aygoren-Pursun, E, Rusicke, E, Heller, C, Klingebiel, T (2009) C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis. Transfusion 49: pp. 1987-1995 CrossRef
    40. Bork, K, Meng, G, Staubach, P, Hardt, J (2005) Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion 45: pp. 1774-1784 CrossRef
    41. Maurer, M, Parish, LC (2013) The dermatology view of hereditary angio-oedema: practical diagnostic and management considerations. J Eur Acad Dermatol Venereol 27: pp. 133-141 CrossRef
    42. Craig, TJ, Rojavin, MA, Machnig, T, Keinecke, HO, Bernstein, JA (2013) Effect of time to treatment on response to C1 esterase inhibitor concentrate for hereditary angioedema attacks. Ann Allergy Asthma Immunol 111: pp. 211-215 CrossRef
    43. Moellman, JJ, Bernstein, JA, Lindsell, C, Banerji, A, Busse, PJ, Camargo, CA, Collins, SP, Craig, TJ, Lumry, WR, Nowak, R, Pines, JM, Raja, AS, Riedl, M, Ward, MJ, Zuraw, BL, Diercks, D, Hiestand, B, Campbell, RL, Schneider, S, Sinert, R (2014) A consensus parameter for the evaluation and management of angioedema in the emergency department. J Acad Emerg Med 21: pp. 469-484 CrossRef
    44. Bork, K (2010) Diagnosis and treatment for hereditary angioedema with normal C1-inhibitor. Allergy Asthma Clin Immunol 6: pp. 15-23 CrossRef
    45. Bork, K, Wulff, K, Hardt, J, Witzke, G, Staubach, P (2009) Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy. J Allergy Clin Immunol 124: pp. 129-134 CrossRef
    46. Vitrat-Hincky, V, Gompel, A, Dumestre-Perard, C, Boccon-Gibod, I, Drouet, C, Cesbron, JY (2010) Type III hereditary angio-oedema: clinical and biological features in a French cohort. Allergy 65: pp. 1331-1336 CrossRef
    47. Boccon-Gibod, I, Bouillet, L (2012) Safety and efficacy of icatibant self-administration for acute hereditary angioedema. Clin Exp Immunol 168: pp. 303-307 CrossRef
    48. Bouillet, L, Ponard, D, Drouet, C, Jullien, D, Massot, C (2003) Angioedema and oral contraception. Dermatology 206: pp. 106-109 CrossRef
    49. Bork, K, Hardt, J, Staubach-Renz, P, Witzke, G (2011) Risk of laryngeal edema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate: a retrospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112: pp. 58-64 CrossRef
    50. Farkas, H, Gyeney, L, Gidofalvy, E, Fust, G, Varga, L (1999) The efficacy of short-term danazol prophylaxis in hereditary angioedema patients undergoing maxillofacial and dental procedures. J Oral Maxillofac Surg 57: pp. 404-408 CrossRef
    51. Jurado-Palomo, J, Munoz-Caro, JM, Lopez-Serrano, MC, Prior, N, Cabanas, R, Pedrosa, M (2013) Management of dental-oral procedures in patients with hereditary angioedema due to C1 inhibitor deficiency. J Investig Allergy Clin Immunol 23: pp. 1-6
    52. Farkas, H, Zotter, Z, Csuka, D, Szabo, E, Nebenfuhrer, Z, Temesszentandrasi, G (2012) Short-term prophylaxis in hereditary angioedema due to deficiency of the C1-inhibitor鈥揳 long-term survey. Allergy 67: pp. 1586-1593
    53. Ayg枚ren-P眉rs眉n, E, Martinez Saguer, I, Kreuz, W, Klingebiel, T, Schwabe, D (2013) Risk of angioedema following invasive or surgical procedures in HAE type I and II鈥搕he natural history. Allergy 68: pp. 1034-1039 CrossRef
    54. Maya, K, Nanda, M, Singh, U, Wilmot, J, Bernstein, J (2014) A cross-sectional questionnaire assessing patient and physician use of short-term prophylaxis for hereditary angioedema. Ann Allergy Asthma Immunol 113: pp. 198-203 CrossRef
    55. Gelfand, JA, Sherins, RJ, Alling, DW, Frank, MM (1976) Treatment of hereditary angioedema with danazol.Reversal of clinical and biochemical abnormalities. N Engl J Med 23: pp. 1444-1448 CrossRef
    56. Hosea, SW, Santaella, ML, Brown, EJ, Berger, M, Katusha, K, Frank, MM (1980) Long-term therapy of hereditary angioedema with danazol. Ann Intern Med 93: pp. 809-812 CrossRef
    57. Sheffer, AL, Fearon, DT, Austen, KF (1981) Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. J Allergy Clin Immunol 68: pp. 181-187 CrossRef
    58. Cicardi, M, Bergamaschini, L, Cugno, M, Hack, E, Agostoni, G, Agostoni, A (1991) Long-term treatment of hereditary angioedema with attenuated androgens: a survey of a 13-year experience. J Allergy Clin Immunol 87: pp. 768-773 CrossRef
    59. Bork, K, Bygum, A, Hardt, J (2008) Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol 100: pp. 153-161 CrossRef
    60. Fust, G, Farkas, H, Csuka, D, Varga, L, Bork, K (2011) Long-term efficacy of danazol treatment in hereditary angioedema. Eur J Clin Invest 41: pp. 256-262 CrossRef
    61. Cicardi, M, Castelli, R, Zingale, LC, Agostoni, A (1997) Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. J Allergy Clin Immunol 99: pp. 194-196 CrossRef
    62. Farkas, H, Czaller, I, Csuka, D, Vas, A, Valentin, S, Varga, L (2010) The effect of long-term danazol prophylaxis on liver function in hereditary angioedema-a longitudinal study. Eur J Clin Pharmacol 66: pp. 419-426 CrossRef
    63. Gandhi, PK, Gentry, WM, Bottorff, MB (2012) Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database. Pharmacotherapy 32: pp. 902-909 CrossRef
    64. Kalaria, S, Craig, T (2013) Assessment of hereditary angioedema treatment risks. Allergy Asthma Proc 34: pp. 519-522 CrossRef
    65. Sheffer, AL, Austen, KF, Rosen, FS (1972) Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med 287: pp. 452-454 CrossRef
    66. Gwynn, CM (1974) Therapy in hereditary angioneurotico edema. Arch Dis Child 49: pp. 636-640 CrossRef
    67. Bowen, T, Cicardi, M, Farkas, H, Bork, K, Kreuz, W, Zingale, L, Varga, L, Martinez-Saguer, I, Ayg枚ren-P眉rs眉n, E, Binkley, K, Zuraw, B, Davis, A, Hebert, J, Ritchie, B, Burnham, J, Castaldo, A, Menendez, A, Nagy, I, Harmat, G, Bucher, C, Lacuesta, G, Issekutz, A, Warrington, R, Yang, W, Dean, J, Kanani, A, Stark, D, McCusker, C, Wagner, E, Rivard, GE (2004) Canadian 2003 International Consensus Algorithm For the Diagnosis, Therapy, and Management of Hereditary Angioedema. J Allergy Clin Immunol 114: pp. 629-637 CrossRef
    68. Blasco, AJ, L谩zaro, P, Caballero, T, Guilarte, M (2013) Social costs of icatibant self-administration vs. health professional-administration in the treatment of hereditary angioedema in Spain. Health Econ Rev 3: pp. 2 CrossRef
    69. Riedl, M (2012) Hereditary angioedema therapies in the United States: movement toward an international treatment consensus. J Clin Ther 34: pp. 623-630 CrossRef
    70. Craig, TJ (2013) Recent advances in hereditary angioedema self-administration treatment: summary of an International Hereditary Angioedema Expert Meeting. Int Arch Allergy Immunol 161: pp. 26-27 CrossRef
    71. Teitel, JM, Barnard, D, Israels, S, Lillicrap, D, Poon, MC, Sek, J (2004) Home management of haemophilia. J Hemophilia 10: pp. 118-133 CrossRef
    72. Tourangeau, LM, Castaldo, AJ, Davis, DK, Koziol, J, Christiansen, SC, Zuraw, BL (2012) Safety and efficacy of physician-supervised self-managed C1 inhibitor replacement therapy. Int Arch Allergy Immunol 157: pp. 417-424 CrossRef
    73. Caballero, T, Ayg枚ren-P眉rs眉n, E, Bygum, A, Beusterien, K, Hautamaki, E, Sisic, Z, Wait, S, Boysen, HB (2014) The humanistic burden of hereditary angioedema: results from the Burden of Illness Study in Europe. Allergy Asthma Proc 35: pp. 47-53 CrossRef
    74. Maurer, M, Aberer, W, Bouillet, L, Caballero, T, Fabien, V (2013) Hereditary Angioedema Attacks Resolve Faster and Are Shorter after Early Icatibant Treatment. PLoS One 8: pp. e53773 CrossRef
    75. Bygum, A, Andersen, KE, Mikkelsen, CS (2009) Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol 19: pp. 147-151
    76. Zuraw, BL, Banerji, A, Bernstein, JA, Busse, PJ, Christiansen, SC, Davis-Lorton, M, Frank, MM, Li, HH, Lumry, WR, Riedl, M (2013) US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. J Allergy Clin Immunol In Prac 1: pp. 458-467 CrossRef
    77. Soucie, JM, Symons, J, Evatt, B, Brettler, D, Huszti, H, Linden, J (2001) Home-based factor infusion therapy and hospitalization for bleeding complications among males with hemophilia. J Hemophilia 7: pp. 198-206 CrossRef
    78. / http://clinicaltrials.gov/show/NCT01912456.
    79. / http://clinicaltrials.gov/show/NCT01095497.
    80. Longhurst, HJ, Farkas, H, Craig, T, Ayg枚ren-P眉rs眉n, E, Bethune, C, Bjorkander, J, Bork, K, Bouillet, L, Boysen, H, Bygum, A, Caballero, T, Cicardi, M, Dempster, J, Gompels, M, Gooi, J, Grigoriadou, S, Huffer, U, Kreuz, W, Levi, MM, Long, J, Martinez-Saguer, I, Raguet, M, Reshef, A, Bowen, T, Zuraw, B (2010) HAE international home therapy consensus document. Allergy, Asthma Clin Immunol 6: pp. 22 CrossRef
    81. Cicardi, M, Craig, TJ, Martinez-Saguer, I, Hebert, J, Longhurst, HJ (2013) Review of recent guidelines and consensus statements on hereditary angioedema therapy with focus on self-administration. Int Arch Allergy Immunol 161: pp. 3-9 CrossRef
    82. Huang, SW (2004) Results of an on-line survey of patients with hereditary angioedema. Allergy Asthma Proc 25: pp. 127-131
    83. Lumry, WR, Castaldo, AJ, Bernon, MK, Blaustein, MB, Wilson, DA, Horn, PT (2010) The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc 5: pp. 407-414 CrossRef
    84. Nordenfelt, P, Dawson, S, Wahlgren, CF, Lindfors, A, Mallbris, L, Bj枚rkander, J (2014) Quantifying the burden of disease and perceived health state in patients with hereditary angioedema in Sweden. Allergy Asthma Proc 35: pp. 185-190 CrossRef
    85. Ayg枚ren-P眉rs眉n, E, Bygum, A, Beusterien, K, Hautamaki, E, Sisic, Z, Wait, S, Boysen, HB, Caballero, T (2014) Socioeconomic burden of hereditary angioedema: results from the hereditary angioedema burden of illness study in Europe. J Orphanet J Rare Dis 99: pp. 99-105 CrossRef
    86. Bygum, A, Ayg枚ren-P眉rs眉n, E, Caballero, T, Beusterien, K, Gholizadeh, S, Musingarimi, P, Wait, S, Boysen, H (2012) The hereditary angioedema burden of illness study in Europe (HAE-BOIS-Europe): background and methodology. BMC Dermatol 12: pp. 4 CrossRef
    87. Bouillet, L, Launay, D, Fain, O, Boccon-Gibod, I, Laurent, J, Martin, L, Montauban, V, Finck, K, Bou茅e, S, Gompel, A, Kanny, G (2013) French National Reference Center for Hereditary Angioedema (CREAK). Hereditary angioedema with C1 inhibitor deficiency: clinical presentation and quality of life of 193 French patients. J Ann Allergy Asthma Immunol 111: pp. 290-294 CrossRef
    88. Prior, N, Remor, E, Gomez-Traseira, C, Lopez-Serrano, C, Cabanas, R, Contreras, J (2012) Development of a disease-specific quality of life questionnaire for adult patients with hereditary angioedema due to C1 inhibitor deficiency (HAE-QoL): Spanish multi-centre research project. Health Qual Life Outcomes 10: pp. 82 CrossRef
    89. Prior, N, Remor, E, P茅rez-Fern谩ndez, E, G贸mez-Traseira, C, Caminoa, MJ, Gay谩, F, Aberer, W, Barrera, OM, Betschel, SD, Bouillet, L, Bygum, A, Farkas, H, Grumach, A, Grivcheva-Panovska, V, Levi, M, Longhurst, H, Malbran, A, Moldovan, D, Porebski, G, Reshef, A, Staubach, P, Zanichelli, A, Zhi, YX, Caballero, T (2014) IHAE-Qol: Specific Health-Related Quality Of Life (HRQoL) Questionnaire In Hereditary Angioedema Due To C1 Inhibitor Deficiency (HAE-C1INH). J Allergy Clin Immunol 133: pp. AB33 CrossRef
    90. Caballero, T, Farkas, H, Bouillet, L, Bowen, T, Gompel, A, Fagerberg, C, Bj枚kander, J, Bork, K, Bygum, A, Cicardi, M, de Carolis, C, Frank, M, Gooi, JH, Longhurst, H, Mart铆nez-Saguer, I, Nielsen, EW, Obtulowitz, K, Perricone, R, Prior, N (2012) International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol 129: pp. 308-320 CrossRef
  • 刊物主题：Allergology; Immunology; Pneumology/Respiratory System;
  • 出版者：BioMed Central
  • ISSN：1710-1492
文摘
Hereditary angioedema (HAE) is a disease which is associated with random and often unpredictable attacks of painful swelling typically affecting the extremities, bowel mucosa, genitals, face and upper airway. Attacks are associated with significant functional impairment, decreased Health Related Quality of Life, and mortality in the case of laryngeal attacks. Caring for patients with HAE can be challenging due to the complexity of this disease. The care of patients with HAE in Canada is neither optimal nor uniform across the country. It lags behind other countries where there are more organized models for HAE management, and where additional therapeutic options are licensed and available for use. The objective of this guideline is to provide graded recommendations for the management of patients in Canada with HAE. This includes the treatment of attacks, short-term prophylaxis, long-term prophylaxis, and recommendations for self-administration, individualized therapy, quality of life, and comprehensive care. It is anticipated that by providing this guideline to caregivers, policy makers, patients and their advocates, that there will be an improved understanding of the current recommendations regarding management of HAE and the factors that need to be considered when choosing therapies and treatment plans for individual patients. The primary target users of this guideline are healthcare providers who are managing patients with HAE. Other healthcare providers who may use this guideline are emergency physicians, gastroenterologists, dentists and otolaryngologists, who will encounter patients with HAE and need to be aware of this condition. Hospital administrators, insurers and policy makers may also find this guideline helpful.

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址：北京市海淀区学院路29号 邮编：100083

电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700